OPTHEA LIMITED OPT · Stock Open OPTHEA LIMITED in new tab
OPTHEA LIMITED Analysis (OPT)
Is OPTHEA LIMITED a good investment? OPTHEA LIMITED (OPT) is currently trading at 3.41 USD.
Earnings Schedule: OPTHEA LIMITED is expected to release its next earnings report on Feb. 26, 2026.
Investor FAQ
Does OPTHEA LIMITED pay a dividend?
No, it does not currently pay a dividend.
What asset class is OPTHEA LIMITED?
OPTHEA LIMITED is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Feb. 26, 2026.
Company Profile
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 16, 2020 | 0.620000 |
| Sept. 13, 2016 | 1.020000 |
Community Discussion